Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Probing mucin-type O-linked glycosylation in living animals
2006 StandoutNobel
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 + CD25 + CD4 + regulatory T cells
2005 StandoutNobel
The DNA-damage response in human biology and disease
2009 StandoutNature
Dendritic cells as therapeutic vaccines against cancer
2005
Growth Dominance of the Metastatic Cancer Cell: Cellular and Molecular Aspects
1990
Physical Principles of Membrane Shape Regulation by the Glycocalyx
2019 StandoutNobel
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Mucin-1 is expressed on dendritic cells, both in vitro and in vivo
2004
Cancer immunotherapy: breaking the barriers to harvest the crop
2004 StandoutNobel
Regulatory T Cells and Immune Tolerance
2008 StandoutNobel
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
Treatment of Non-Hodgkin's Lymphoma
1993
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
2008
Biology of Natural Killer Cells
1989 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Chemotherapy and the war on cancer
2005 Standout
Revealing the human mucinome
2022 StandoutNobel
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Virus-induced autoantibody response to a transgenic viral antigen
1990 StandoutNatureNobel
Classification of anticancer drugs—a new system based on therapeutic targets
2003
Cancer immunotherapy comes of age
2011 StandoutNature
Retroviral vectors displaying functional antibody fragments
1993 StandoutNobel
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
1991 Standout
Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients
2014
Glycocalyx Engineering with a Recycling Glycopolymer that Increases Cell Survival In Vivo
2015 StandoutNobel
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
1995 Standout
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Mucins in cancer: protection and control of the cell surface
2003
History of myeloid-derived suppressor cells
2013
Cancer-related inflammation
2008 StandoutNature
MUC1, The Renaissance Molecule
2001
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Lymphokine gene therapy for cancer
1990
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Treatment of corticosteroid-resistant polymyositis with methotrexate
1971
Hierarchical Assembly of Model Cell Surfaces: Synthesis of Mucin Mimetic Polymers and Their Display on Supported Bilayers
2007 StandoutNobel
Interleukin-10 and the immune response against cancer: a counterpoint
2005
Control of the Molecular Orientation of Membrane-Anchored Biomimetic Glycopolymers
2009 StandoutNobel
Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T cells bearing receptors for IgM or IgG.
1977 Standout
Current Developments in Cancer Vaccines and Cellular Immunotherapy
2003
Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
2001
Quantitative Analysis of Melanoma-Induced Cytokine-Mediated Immunosuppression in Melanoma Sentinel Nodes
2005
Polymyositis and Dermatomyositis
1975 Standout
Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes damage after adoptive transfer.
1982 StandoutNobel
Density Variant Glycan Microarray for Evaluating Cross-Linking of Mucin-like Glycoconjugates by Lectins
2012 StandoutNobel
THE EFFECT OF AMETHOPTERIN ON THE IMMUNE RESPONSE*
1971 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
2012 StandoutNobel
Cancer Metastasis: Experimental Approaches, Theoretical Concepts, and Impacts for Treatment Strategies
1985
HLA-Binding Properties of Tumor Neoepitopes in Humans
2014
Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells
2002 StandoutNobel
Expression of a Microinjected Porcine Class I Major Histocompatibility Complex Gene in Transgenic Mice
1985 StandoutScienceNobel
Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells
2003
Potentiation of a primary in vivo antibody response by alloantisera against gene products of the I region of the H-2 complex.
1977 StandoutNobel
Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells
2006
Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.
1975
Specific recognition of the product of a transferred major histocompatibility complex gene by cytotoxic T lymphocytes.
1982
Cancer, Clinical Pharmacology, and Aging
1987
Study on cellular events in post-thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis.
1982 StandoutNobel
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
2009
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal
2014
Chemically tunable mucin chimeras assembled on living cells
2015 StandoutNobel
Bone Marrow Transplant
1990 Standout
Immunological Unresponsiveness
1973
Cancer Genome Landscapes
2013 StandoutScience
CD4 cells can be more efficient at tumor rejection than CD8 cells
2007
Interfacing Carbon Nanotubes with Living Cells
2006 StandoutNobel
Low Zone Tolerance and Suppressor T Cells
1975
Neoantigens in cancer immunotherapy
2015 StandoutScience
The Biology and Detection of Immune Complexes
1980
Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma:In vivopersistence, migration, and antitumor effect of transferred T cells
2002
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
1985 Standout
Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses
2006 StandoutNobel
Noncovalent Cell Surface Engineering: Incorporation of Bioactive Synthetic Glycopolymers into Cellular Membranes
2008 StandoutNobel
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
The In Vitro Generation of Effector Lymphocytes and Their Employment in Tumor Immunotherapy
1983
Works of Malcolm S. Mitchell being referenced
Studies on the relationship of human natural killer and lymphokine-activated killer cells with lysosomal staining and analysis of surface marker phenotypes
1988
Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma
2004
Combinations of anticancer drugs and immunotherapy
2003
Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide
1998
Therapeutic vaccines for melanoma: progress and problems
1996
Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients
1991
Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma
2002
Activation of suppressor T cells by tumour cells and specific antibody
1974 Nature
Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha.
2002
Immunosuppressive Effects of Cytosine Arabinoside and Methotrexate in Man
1969
Suppressor T cells induced by soluble immune complexes can adoptively transfer inhibition of cytophilic antibody receptors on macrophages
1979
Opposite Effects of Different Strains or Batches of Same Strain of BCG on In Vitro Generation of Syngeneic and Allogeneic Antitumor Cytotoxicity23
1980
Hybridomas in Cancer Diagnosis and Treatment
1982
Cytotoxic activity of human pulmonary alveolar macrophages.
1985
Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope
2002
The Production of Tolerance to Human Erythrocytes in the Rat with Cytosine Arabinoside or Cyclophosphamide
1969
Human monoclonal antibodies directed against melanoma tumor-associated antigens.
1986
Combination sequential chemotherapy in advanced reticulum cell sarcoma
1972
Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope
2002
Induction of suppressor cells by intravenous administration of Bacillus calmette-guérin and its modulation by cyclophosphamide
1979
Immunological responses to l-asparaginase
1971